Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

European Union Approves New Hemophilia Recombinant Factor Product

December 30, 2021

The European Commission approved Kovaltryâ„¢ antihemophilic factor (recombinant) for the treatment of hemophilia A in patients of all ages. The drug is an unmodified full-length recombinant factor VIII product.

The approval was based on results from the Long-Term Efficacy Open-Label Program in Severe Hemophilia A Disease (LEOPOLD) clinical trials, which were carried out in more than 200 children and adults with severe hemophilia A from 60 sites in 25 countries worldwide. In the LEOPOLD trials, the drug demonstrated control of and protection from bleeds when used prophylactically two to three times per week. The drug's parent product is administered three times a week, so it offers a slight dosing advantage and flexibility.

The drug's manufacturer is also pursuing regulatory approval in the United States and Canada.

Source: Bayer press release, February 23, 2016.

Advertisement intended for health care professionals

Connect with us:

CURRENT ISSUE
November 2024

Advertisement intended for health care professionals

Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals